Get the Stockscreener App
5.64
8.67%
0.45
After Hours:
5.64
Rxsight Inc stock is traded at $5.64, with a volume of 984.10K.
It is up +8.67% in the last 24 hours and up +5.22% over the past month.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
See More
Previous Close:
$5.19
Open:
$5.25
24h Volume:
984.10K
Relative Volume:
0.93
Market Cap:
$233.48M
Revenue:
$134.48M
Net Income/Loss:
$-38.94M
P/E Ratio:
-5.9157
EPS:
-0.9534
Net Cash Flow:
$-19.34M
1W Performance:
+0.53%
1M Performance:
+5.22%
6M Performance:
-38.83%
1Y Performance:
-29.23%
1-Day Range:
$5.25
$5.68
1-Week Range:
$5.055
$5.68
52-Week Range:
$4.48
$13.22
Rxsight Inc Stock (RXST) Company Profile
Name
Rxsight Inc
Sector
Industry
Phone
949-521-7822
Address
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
5.64 | 214.85M | 134.48M | -38.94M | -19.34M | -0.9534 |
ABT
Abbott Laboratories
|
104.49 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
336.74 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
84.22 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
45.51 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.04 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | William Blair | Mkt Perform |
| Jul-15-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-25 | Downgrade | Jefferies | Buy → Hold |
| Jul-09-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-09-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-09-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-19-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-15-25 | Initiated | Piper Sandler | Neutral |
| Apr-09-25 | Downgrade | UBS | Buy → Neutral |
| Apr-04-25 | Downgrade | JP Morgan | Overweight → Underweight |
| Apr-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-20-24 | Downgrade | Stifel | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | UBS | Buy |
| Oct-29-24 | Initiated | Jefferies | Buy |
| Aug-20-24 | Reiterated | Needham | Buy |
| Aug-06-24 | Reiterated | Needham | Buy |
| May-07-24 | Reiterated | BTIG Research | Buy |
| Dec-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Initiated | Morgan Stanley | Overweight |
| Apr-13-23 | Initiated | Oppenheimer | Outperform |
| Dec-12-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-08-22 | Initiated | Needham | Buy |
View All
Rxsight Inc Stock (RXST) Latest News
RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer - hrtoday.in
Leadership watch: RxSight, Exonate tap new CEOs; CooperVision, Lumenis, and OSU fill top roles - Glance by Eyes On Eyecare
Rxsight Inc (RXST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
RxSight grants new CEO Aziz Mottiwala stock options for 571,286 shares at $5.19 each - Bitget
RxSight grants inducement stock options and RSU... - Pluang
New RxSight CEO's 2.31M RSU award vests over three years - Stock Titan
Rxsight Inc (RXST) Income Statement - TradingKey
RxSight (RXST) Stock Fair Value Falls After Soft Q2 Trends And Guidance Cut - Yahoo Finance
Rxsight Inc (RXST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
Rxsight Inc (RXST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Form 4 Rxsight Inc For: 24 July By Investing.com - Investing.com Nigeria
RxSight, Inc. (RXST) awards CEO 2,312,138 RSUs and 571,286 options - Stock Titan
Lost Money on RxSight, Inc. (RXST)? Urged to Join Class Action Before September 22, 2025Contact Levi & Korsinsky - The National Law Review
RXST|Rxsight Inc|Price:5.205|Chg%:-0.165 - TradingKey
Midday Stock Roundup: Shares of loanDepot up 7% - Orange County Business Journal
Rxsight Inc (RXST) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rxsight Inc (RXST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RXST|Rxsight Inc|Price:5.155|Chg%:-0.215 - TradingKey
(RXST) Movement as an Input in Quant Signal Sets - Stock Traders Daily
RxSight Lands Tarsus Commercial Leader as CEO - Orange County Business Journal
RxSight (RXST) surges 6.1%: Is this an indication of further gains? - MSN
RxSight appoints new CEO - MSN
RXST stock holds as RxSight advances its light-adjustable lens business - Ad-hoc-news.de
BlackRock Portfolio Management (RXST) discloses 7.2% beneficial stake in RxSight - Stock Titan
BTIG Maintains RxSight(RXST.US) With Hold Rating, Announces Target Price $5.25 - Moomoo
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Kazia Therapeutics (KZIA) and Crescent Biopharma (CBIO) - The Globe and Mail
RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains? - Yahoo Finance
BTIG Maintains RxSight(RXST.US) With Hold Rating, Maintains Target Price $5.25 - Moomoo
RXST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
RxSight Tags Aziz Mottiwala as President and CEO, Ron Kurtz, MD, as CMO - VisionMonday.com
RxSight names Aziz Mottiwala as new CEO effective July 20 - Investing.com UK
RxSight names Aziz Mottiwala as new CEO effective July 20 By Investing.com - Investing.com Australia
RxSIGHT announces significant leadership appointments - Bitget
Ron Kurtz Steps Down as RxSight CEO - Orange County Business Journal
RxSight Names Aziz Mottiwala as CEO - Moomoo
RxSight (NASDAQ: RXST) hires new CEO, sets $14M equity package - Stock Titan
Press Release: RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer - Moomoo
RxSight CEO Ron Kurtz to Continue as Chief Medical Officer - Stock Titan
Alcon & RxSight Collaborate to Develop Adjustable PCIOL Technology - Zacks Investment Research
Alcon collaborates with RxSight to develop adjustable PCIOLs - MSN
Alcon, RxSight announce collaboration to develop adjustable presbyopia-correcting IOLs - Ophthalmology Times Europe
RxSight Q2 sales sink 20% as Alcon deal bolsters 2026 outlook - MSN
RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook - TradingView
RxSight (RXST) Faces Investigation Over Board's Fiduciary Duties - GuruFocus
Glancy Prongay Wolke & Rotter LLP Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors - The AI Journal
RxSight: After Dropping To The Bottom, It's Time To Pick It Up (NASDAQ:RXST) - Seeking Alpha
RxSight Inc. (RXST) Holds Near Key Support Amid Slight Decline — Technical Picture in FocusDealer Positioning - dars.gov.et
Is Alcon (SWX:ALC) Cheap Following Its RxSight Collaboration And Premium P E? - simplywall.st
Is Alcon (SWX:ALC) Undervalued After Its RxSight Collaboration? - Yahoo Finance
Rxsight Inc Stock (RXST) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
4.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):